Stepan Company (SCL) Q4 2024 earnings summary

Executive summary

• Full-year 2024 net income rose 25% to $50.4M, while adjusted net income was flat at $50.5M; adjusted EBITDA was $187M, up 4% year-over-year, despite significant one-time costs and pre-operating expenses at the new Pasadena site.

• Free cash flow rebounded to $39.3M in 2024 from a negative $85.5M in 2023, a $124.8M increase, in line with expectations.

• Surfactants and Specialty Products delivered strong double-digit Adjusted EBITDA growth, offset by weaker demand in Polymers; global volumes grew 1%, led by 2.5% growth in Surfactants.

• $48M in pre-tax cost savings were achieved in 2024, mainly through supply chain and workforce productivity actions, despite one-time costs from a flood and a criminal fraud event.

• The Board declared a quarterly cash dividend of $0.385 per share, continuing a 57-year streak of dividend increases.

Financial highlights

• Q4 2024 adjusted EBITDA was $35M, down 7% year-over-year; Q4 adjusted net income was $2.8M, down 63% due to higher pre-operating, tax, and CEO transition costs.

• Q4 net income was $3.4M, reversing a $1.2M loss in Q4 2023; Q4 free cash flow was $32.1M.

• Full-year net sales were $2.18B, down 6% from 2023; Q4 net sales were $525.6M, down 1% year-over-year.

• Cash from operations for 2024 was $162.1M, down 7% year-over-year.

• Q4 operating income was $7.7M, up from $0.2M in Q4 2023; full-year operating income was $70.5M, up 20%.

Outlook and guidance

• Pasadena alkoxylation facility is expected to start up in Q1 2025, with full contribution run rate in the second half of 2025.

• Management expects adjusted EBITDA and adjusted net income growth, positive free cash flow, and improvement across all segments in 2025.

• 2025 capital expenditures are forecasted at $125–135M; effective tax rate expected to rise to 24–26%.